Scarica l'app Stockscreener
0.98
1.03%
0.01
Dopo l'orario di chiusura:
.98
Renovorx Inc Borsa (RNXT) Ultime notizie
RNXT Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Yahoo Finance
Street Watch: How does RenovoRx Inc perform in inflationary periods2026 Price Action Summary & Reliable Price Breakout Signals - baoquankhu1.vn
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial - The Globe and Mail
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
RenovoRx Reports Solid First Full Year of RenovoCath Commercialization - National Today
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Trade Recap: What chart patterns are forming on RenovoRx IncMarket Performance Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Published on: 2026-03-31 14:32:17 - baoquankhu1.vn
RNXT: 2026 revenue is projected to triple as commercial site expansion accelerates and funding strengthens - TradingView
RNXT: 2025 revenue reached $1.1M, with 2026 guidance of $3–$4M and rapid commercial site expansion - TradingView
Earnings call transcript: RenovoRx Q4 2025 results show revenue growth - Investing.com
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update - Investing News Network
RNXT: 2025 revenue rose to $1.1M, but net loss increased as commercialization and R&D spending grew - TradingView
RenovoRx (NASDAQ: RNXT) surges 2025 revenue and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx (NASDAQ: RNXT) grows RenovoCath use and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
RNXT: 2025 revenue reached $1.1M as RenovoCath adoption expanded; TIGER-PAC trial nears completion - TradingView
RenovoRx 2025 net loss widens on higher operating expenses - TradingView
BRIEF-RenovoRx FY Net Income USD -11.168 Million - TradingView
Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish - Stock Titan
RenovoRx Q4 2025 Earnings Call Transcript - marketbeat.com
Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result - gurufocus.com
RenovoRx Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) CFO granted 12,380 RSUs, now reports 134,580 shares - Stock Titan
RenovoRx (RNXT) CFO discloses 25,000 shares bought pre-role - Stock Titan
RenovoRx appoints Dr. Ramtin Agah as executive chairman and updates compensation - Investing.com
[8-K] RenovoRx, Inc. Reports Material Event - Stock Titan
RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 - MarketScreener
RenovoRx surpasses 100 patients in Phase III pancreatic trial By Investing.com - Investing.com South Africa
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment - Investing News Network
Sell Signal: Is RenovoRx Inc stock a value trapInsider Selling & Smart Swing Trading Alerts - baoquankhu1.vn
RenovoRx surpasses 100 patients in Phase III pancreatic trial - Investing.com
RenovoRx pancreatic cancer trial passes 100 patients, 2027 data next - Stock Titan
RenovoRx CFO voll acquires shares and warrants in RNXT By Investing.com - Investing.com Australia
RenovoRx CFO voll acquires shares and warrants in RNXT - Investing.com
Laurence Marton buys RenovoRx stock and warrants for $10,000 By Investing.com - Investing.com Australia
Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock By Investing.com - Investing.com Australia
Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock - Investing.com
Laurence Marton buys RenovoRx stock and warrants for $10,000 - Investing.com
RenovoRx (RNXT) executive discloses direct ownership of 25,000 shares - Stock Titan
RenovoRx (RNXT) director adds $10K via rollover IRA private deal - Stock Titan
The most innovative companies in medical devices of 2026 - Fast Company
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - Investing News Network
RenovoRx Raises $10 Million in Oversubscribed Private Placement - TipRanks
RenovoRx Secures $10 Million Oversubscribed Private Placement to Accelerate RenovoCath Commercialization and Advance Phase III Pancreatic Cancer Trial - Minichart
Trend Recap: Can RenovoRx Inc expand its profit margins2026 Year in Review & Growth Focused Entry Reports - baoquankhu1.vn
RenovoRx Raises ~$10 Million in Private Placement; Sells Stock and Warrants at $0.938 Per Share - TradingView
RenovoRx (Nasdaq: RNXT) nets $10M private placement with milestone warrants - Stock Titan
RenovoRx (RNXT) Expected to Announce Quarterly Earnings on Monday - Defense World
RenovoRx (RNXT) Valuation—Phase III Triumph Priced In as Funding Is Already Accounted For, Minimizing Downside Risk - Bitget
Panic Selling: How does RenovoRx Inc perform in inflationary periods2026 Geopolitical Influence & Entry and Exit Point Strategies - baoquankhu1.vn
Downgrade Watch: Can RenovoRx Inc deliver alphaWeekly Trade Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET - Investing News Network
Draganfly to Host Shareholder Update Call on March 24, 2026 - weeklyvoice.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):